Assessing the Value of Treatments for Liver Diseases

On the eve of ICER’s public meeting to discuss its evaluation of these treatments, National Pharmaceutical Council President Dan Leonard sat down with Ms. Cryer to ask her thoughts about ICER, value assessments and how patients can become more engaged in these evaluations.